ATLANTA, Feb. 7, 2013 (GLOBE NEWSWIRE) -- OTC Stock Review announces that it has published a report on YaFarm Technologies (OTC:YFRM). YaFarm Technologies, Inc. recently signed a definitive agreement to acquire the Integrative Stem Cell Institute (the ISCI), located at the Galenia Hospital of Cancun, which is one of the pioneers in the field of cell-based regenerative medicine. ISCI's facilities include a Good Processing Practice laboratory with a clean room and fully equipped with state-of-the-art equipment. ISCI's facility was specifically designed to safely process cellular materials for clinical studies and therapeutic use. It can also be used to safely preserve cells for later applications.
We have been interested in the stem cell industry for several years and issued a report last year on shares of Invivo Therapeutics Holdings Corp. Other public stem cell companies investors might be familiar with are Osiris Therapeutics, Inc., Athersys, Inc., and BioMimetic Therapeutics, Inc., just to name a few. There are actually a few dozen more, but none as exciting as YFRM and ISCI, in our opinion.
Keep in mind that ISCI is an adult stem cell facility. The ISCI bases its research, clinical studies and therapeutic applications on stem cells like Bone Marrow Derived Adult Stem Cells (BMDASC), Adipose (Fat) Derived Adult Stem Cells (ADASC), Fetal Cord Blood Derived Adult Stem Cells, Fetal Placenta Derived Adult Stem Cells, and Mesenchymal Stem Cells.
The complete report is available at http://www.otcstockreview.com/YFRM_Review.pdf.
Additional information about the Integrative Stem Cell Institute is available on their website at http://www.iscelli.com
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and YaFarm Technologies. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended as investment advice. This document contains information obtained from public sources about YaFarm Technologies, but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of YaFarm Technologies, as profiled. OTC Stock Review has been compensated three thousand dollars to perform investor relations services for YaFarm Technologies. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled Company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov or http://www.otcmarkets.com. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm